Home About Us Research & Development Investors & Media Careers Contact Us

News Highlights

September 17, 2014
Concert Pharmaceuticals Announces Initiation of
CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration

August 26, 2014
Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration

August 12, 2014
Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Company Update; Conference Call Scheduled Today at 8:30 a.m. EDT, Including Discussion of Positive Results from Phase 1 Brain Imaging Trial of CTP-354



Welcome to Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company. We apply our extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs.

In the News

Mass High Tech BioFlash: Concert -Good news for two of its partnered drugs
September 22, 2104

MedChem News
Deuterium Medicinal Chemistry: A New Approach to Drug Discovery and Development Read more

Issued U.S. Patents

Concert is building a broad patent estate. View List


Concert has presented at a number scientific meetings. View Poster presentations

  ©2009 Concert Pharmaceuticals, Inc.
Design by Digizyme
Home     Sitemap